scholarly journals Metformin and Serum Vitamin B12 Levels in Type II Diabetic Patients

2000 ◽  
Vol 10 (1) ◽  
pp. 31-35
Author(s):  
Didem Dereli ◽  
Harun Yenice ◽  
Sinan Erten ◽  
Faruk Ergönen ◽  
Ziya Günal
Keyword(s):  
Vitamin B12 ◽  
Serum Vitamin ◽  
Diabetic Patients ◽  
Type Ii

A STUDY ON THE CORRELATION OF DIABETIC RETINOPATHY IN TYPE II DIABETES MELLITUS WITH SERUM VITAMIN D LEVELS

2021 ◽  
pp. 78-80
Author(s):  
Barnali Bhattacharyya Thakur ◽  
Keshab Bora ◽  
Sherin Gogoi
Keyword(s):  
Diabetes Mellitus ◽  
Vitamin D ◽  
Diabetic Retinopathy ◽  
Type Ii Diabetes ◽  
Serum Vitamin ◽  
Diabetic Patients ◽  
Type I ◽  
Type Ii ◽  
Serum Vitamin D ◽  
Vitamin D Levels

INTRODUCTION: Diabetes mellitus is a major public health problem with signicant morbidity and mortality. Diabetic retinopathy is one of the most common microvascular complications of Diabetes mellitus causing blindness. Vitamin D is a fat soluble vitamin involved in maintenance of mineral homeostasis and bone remodelling. Vitamin D deciency is highly prevalent in type I and type II Diabetes. 38 diabetic without ocular disease a METHOD: nd 30 diabetic with retinopathy were taken as cases and 38 age sex matched healthy persons were taken as controls. Serum Vit D and glucose were estimated and retinopathy was diagnosed by fundus examination. The results were statistically analysed. Statistica RESULTS: l analysis of the results shows a negative correlation between FBS and HbA1C with Vitamin D level in diabetic retinopathy patients. Patients CONCLUSION: with Diabetic retinopathy has lower serum Vitamin D level than diabetic patients without retinopathy.

Long Term Effects of Oral Vitamin E Supplement in Type II Diabetic Patients

2005 ◽  
Vol 75 (5) ◽  
pp. 341-346 ◽  
Author(s):  
Boshtam ◽  
Rafiei ◽  
Golshadi ◽  
Ani ◽  
Shirani ◽  
...  
Keyword(s):  
Vitamin E ◽  
Blood Lipids ◽  
Serum Insulin ◽  
Serum Vitamin ◽  
Enzyme Linked Immunosorbent Assay ◽  
Controlled Clinical Trial ◽  
Antioxidant Vitamin ◽  
Diabetic Patients ◽  
Type Ii ◽  
Cardiovascular Research

This triple-blind, placebo-controlled clinical trial was conducted to determine the effect of the vitamin E on fasting blood sugar (FBS), serum insulin, and glycated hemoglobin (GHb) in type II diabetic patients (NIDDM). A total of 100 patients, with no complications, aged 20–60 years old were chosen from those consulting the Isfahan Social Security Service Diabetes Clinic and divided randomly into two treated and placebo groups, and matched for age, sex, level of education, and occupation. The treated and placebo groups were given vitamin E tablets (200 IU/day) and placebo respectively. Serum vitamin E, total cholesterol (TC), triglycerides (TG), FBS, insulin, and GHb were measured at the beginning and at the end of the study (a period of 27 weeks); FBS, GHb and insulin levels were also determined several times during the period. Blood lipids and FBS were measured using the ELAN 2000 autoanalyzer at the Isfahan Cardiovascular Research Center, while for measuring insulin the enzyme-linked immunosorbent assay (ELISA) method was used; GHb was determined calorimetrically (thiobarbituric acid), and for vitamin E measurements the Hansen and Warwick method was used, by which the vitamin E was determined fluorometrically. The findings of this study show no effect of vitamin E supplementation in the patients: GHb did not change appreciably, FBS was reduced nonsignificantly (–4.3% in the treated group vs. –14.0% in the placebo group, p < 0.05). In the case of insulin, no increase was seen; instead, a decrease was observed (slightly more than 17% in the two groups, p = 0.15). No changes were observed in the levels of blood lipids. It was concluded that a daily vitamin E supplement of 200 IU for a period of 27 weeks does not affect insulin, GHb, or FBS in type II diabetic patients. However, since this antioxidant vitamin is beneficial in other ways in these patients, it would seem justified to recommend its use. Certainly, more extensive research is necessary to draw definite conclusions.

scholarly journals The epidemiology and importance of vitamin B12 screening in diabetic patients

2021 ◽  
Author(s):  
Abrar A. A. Yamani ◽  
Jameel A. Awadain ◽  
Yousif A. A. Saleh ◽  
Mohammad S. Baothman ◽  
Feras H. Alhussainy ◽  
...  
Keyword(s):  
Vitamin B12 ◽  
Clinical Manifestations ◽  
Vitamin B12 Deficiency ◽  
Diabetic Patients ◽  
Type I ◽  
Type Ii ◽  
Impaired Metabolism ◽  
B12 Deficiency ◽  
Vitamin B12 Screening

Peripheral neuropathy is a commonly reported chronic adverse event among diabetes mellitus (DM) patients secondary to poor glycemic control. It might also result secondary to deficiency of vitamin B12, reportedly common among diabetic patients. Deficiency of vitamin B12 might result from prolonged metformin administration in patients with type II DM (T2DM). It might also result from reduced absorption and impaired metabolism-related events in type I DM (T1DM) patients. This occurs secondary to the presence of associated autoimmune disorders. Vitamin B12 deficiency is a commonly encountered condition among diabetic patients, both T1DM and T2DM, with variable etiologies. Our current study discussed the epidemiology and importance of screening of vitamin B12 in these patients. However, our findings show that screening is not commonly practiced in different settings. Therefore, awareness is low about the benefits and complications of this practice. Therefore, further research is encouraged to alleviate the quality of care in diabetic patients. Screening for vitamin B12 deficiency might intervene against any potential complications, including irreversible, painful, and potentially disabling nerve injury. Accordingly, it is recommended that screening should be initiated since the start of metformin administration and every year or when relevant clinical manifestations were reported.

scholarly journals Review for the management of vitamin B12 deficiency in diabetic patients on metformin

2020 ◽  
Vol 8 (8) ◽  
pp. 3141
Author(s):  
Saad Thamer Sedeeq ◽  
Zohor Ahmed Kamaleldin Mohamed ◽  
Al Anoud Saleh Al Fehaidi ◽  
Mohammad Jamil Mohammad Al Tamimi ◽  
Mohamed Abd Elhamid ◽  
...  
Keyword(s):  
Vitamin B12 ◽  
Serum Vitamin ◽  
Vitamin B12 Deficiency ◽  
Neurological Complications ◽  
Diabetic Patients ◽  
Periodic Monitoring ◽  
B12 Deficiency ◽  
Current Guidelines ◽  
Poor Cognition

Long-term usage of Metformin is associated with lower serum vitamin B12 levels. The lower than normal levels could worsen neurological complications of diabetes, including diabetic neuropathy and poor cognition. Guidelines advise periodic monitoring of vitamin B12 but do not specify frequency, treatment targets or treatment modality. This commentary aims to review the prevalence and the severity of the presentation and to provide evidence-based answers to those clinical questions not answered by current guidelines.

scholarly journals A clinical study to determine metformin as a cause of serum vitamin B12 decrease and effect of combination of metformin and mecobalamin on serum vitamin B12 levels in type 2 diabetics

2017 ◽  
Vol 6 (5) ◽  
pp. 1066
Author(s):  
Mayuresh D. Kiran ◽  
Bhagyashree N. Naik
Keyword(s):  
Clinical Study ◽  
Vitamin B12 ◽  
Serum Vitamin ◽  
Initial Therapy ◽  
Antidiabetic Drugs ◽  
Diabetic Patients ◽  
Metformin Therapy ◽  
Type 2 Diabetics ◽  
Second Period

Background: Several evidences show metformin decreases vitamin B12. Diabetics are also at the risk of developing neuropathy which is treated with vitamin B12. metformin being initial therapy for diabetic patients, it becomes all the more important to know the extent of this decrease. The study was designed with the objective to compare the levels of vitamin B12 in patients on metformin vis-à-vis on antidiabetic drugs other than metformin and to evaluate the increase in vitamin B12 levels after prescribing a combination of metformin and mecobalamin, in T2DM patients.Methods: Of 500 enrolled, 321 patients completed the study for duration of 6 months, divided in two periods of 3 months each. At the end first period of 3 months the vitamin B12 levels were compared form Metformin vs. that of other antidiabetics. In second period of 3 months a combination of metformin and mecobalamin was given instead of plain metformin and vitamin B12 levels were repeated at the end of this period.Results: There was reduction in vitamin B12 levels with metformin with levels of 272.5pg/ml compared to 714.6pg/ml with other antidiabetics at the end of first period. The levels increased from 272.5pg/ml to 615.9 pg/ml at the end of second period after receiving the combination of metformin and mecobalamin.Conclusions: T2DM patients being treated with metformin had a greater risk of reduction in vitamin B12 levels and addition of vitamin B12 in the form of mecobalamin would decrease the reduction in vitamin B12 levels associated with Metformin therapy.

scholarly journals Prevalence of Vitamin B12 deficiency in Type II diabetic patients using metformin.

2021 ◽  
Vol 28 (09) ◽  
pp. 1322-1325
Author(s):  
Tahir Ullah Khan ◽  
Rozina Arshad ◽  
Saleem Uz Zaman Adhami
Keyword(s):  
Vitamin B12 ◽  
Vitamin B12 Deficiency ◽  
Cross Sectional Study ◽  
Protective Role ◽  
Diabetic Patients ◽  
Type Ii ◽  
Cross Sectional ◽  
B12 Deficiency ◽  
Diabetic Population

Objectives: To determine the prevalence of Vitamin B12 deficiency in type II diabetic patients using metformin. Study Design: Cross Sectional study. Setting: Endocrinology Unit Shalamar Hospital Lahore. Period: July to September 2017. Material & Methods: All of our patients were having previously diagnosed type II diabetes and using metformin for more than six months. Using strict exclusion criteria, vitamin B12 levels of patients were measured and analyzed. Results: It was evident from the present study that 27.33% of type II diabetic patients using metformin were having vitamin B12 levels less than 150pg/ml. Furthermore, our study showed that smokers are more liable to develop vitamin B12 deficiency than the nonsmokers. Also, use of multivitamins (containing vitamin B12) had a protective role against vitamin B12 deficiency. Conclusions: Long term use of metformin in type II diabetic patients is strongly associated with Vitamin B12 deficiency, therefore endocrinologists and physicians should take into consideration this significant adverse effect of metformin and screen for vitamin B12 deficiency in diabetic population before starting metformin therapy.

scholarly journals HAEMATOLOGICAL PARAMETERS AND VITAMIN B12 LEVELS IN TYPE II DIABETIC PATIENTS ON METFORMIN- A PROSPECTIVE CASE CONTROL STUDY

2018 ◽  
Vol 5 (31) ◽  
pp. 2317-2323
Author(s):  
Vijaya Lakshmi Koduri ◽  
Srinivas N. S Nori ◽  
Aditya Sai Rama Krishna K ◽  
Suhas Madaboina ◽  
Sindhuja A. B. K ◽  
...  
Keyword(s):  
Vitamin B12 ◽  
Case Control Study ◽  
Case Control ◽  
Haematological Parameters ◽  
Diabetic Patients ◽  
Type Ii ◽  
Control Study ◽  
Prospective Case Control Study

scholarly journals PREVALENCE AND RISK FACTORS OF VITAMIN B12 DEFICIENCY AMONG PATIENTS WITH TYPE II DIABETES ON METFORMIN: A STUDY FROM NORTHERN REGION OF UNITED ARAB EMIRATES

2018 ◽  
Vol 11 (8) ◽  
pp. 225 ◽  
Author(s):  
Moayad Shahwan ◽  
Nageeb Hassan ◽  
Adel Noshi
Keyword(s):  
Vitamin B12 ◽  
United Arab Emirates ◽  
Vitamin B12 Deficiency ◽  
Northern Region ◽  
Term Treatment ◽  
Diabetic Patients ◽  
Type Ii ◽  
Cross Sectional ◽  
Long Term Treatment ◽  
B12 Deficiency

Objectives: This study focused on the prevalence of Vitamin B12 deficiency in UAE patients with type 2 diabetes mellitus (T2DM) who were treated with or without metformin.Methods: A cross-sectional study was conducted on 213 patients having diabetes type II were randomly selected to be part of the study in Northern Regions of the UAE, from June 2014 to February 2015. The patients aged >45 years and who had taken metformin for at least 3 months were recruited with regular follow-up at the outpatient clinic. The patients were included in a survey after which they had their serum B12 levels measured. Serum B12 levels <150 pg/ml are defined as the B12 deficiency.Results: About 48% of diabetic patients had confirmed the B12 insufficiency through laboratory tests. The patients on metformin had statistically lower values of B12 (p=0.002). The majority of participants n (%) took metformin had neuropathy, hypertension, dyslipidemia, numbness or paresthesia, and depression, or mood changes 140 (70%), 183 (91.5%), 134 (67%), 136 (68%), 161 (80.5%), and 120 (60%), respectively.Conclusion: Our study shows that for the patients with T2DM, long-term treatment with metformin is associated with higher chances of developing Vitamin B12 deficiency. Clinicians should, therefore, recognize this significant element and should screen diabetics who are on metformin treatment for any B12 insufficiency, which may be hidden, especially patients coming with neurologic symptoms.

Sign in / Sign up

Export Citation Format

Share Document